Arbutus Biopharma (ABUS) Stock: Buy, Sell, or Hold?
ABUS - Arbutus Biopharma Corporation Common Stock
$4.20
-0.01 (-0.24%)
▼
5d:
-0.47%
30d:
-13.93%
90d:
-4.76%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABUS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ABUS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.20, which is considered oversold relative to its 30-day fair value range of $4.22 to $4.93.
Technical Outlook: Technically, ABUS is showing sideways momentum. Immediate support is located at $4.05, while resistance sits at $4.37.
Market Sentiment: ABUS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.45 (+29.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABUS is showing sideways momentum. Immediate support is located at $4.05, while resistance sits at $4.37.
Market Sentiment: ABUS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.45 (+29.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.22 -
$4.93
Company Quality Score
70/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (91/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.7% below Wall St target ($5.45)
- BULLISH: Bottoming setup score 91/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$4.22 -
$4.93
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.05
Resistance Level
$4.37
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-37.84
Wall Street Target
$5.45
(+29.7%)
Revenue Growth (YoY)
-90.6%
Profit Margin
84.2%
Share & Embed Analysis
Last updated: October 24, 2026 11:27 AM ET
Data refreshes hourly during market hours. Next update: 12:27 PM
Data refreshes hourly during market hours. Next update: 12:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 59 HOLD |
Advanced ABUS Option Strategies
Professional options setups generated by AI based on today's ABUS price and gamma walls.
